Can Resource-Constrained Countries Afford Better First-Line Antiretroviral Therapy Regimens for HIV/AIDS?
Evidence from the Center for Global Health and Development’s Work in Zambia Presented by Sydney Rosen, research associate professor of international health. Most resource-constrained countries use stavudine (d4T) in first-line antiretroviral therapy (ARV) regimens for HIV/AIDS despite its high burden of toxicities because it is inexpensive and effective. In 2007, Zambia became the first country to replace d4T with tenofovir in first-line ART. Tenofovir is much more expensive than d4T, and the change in treatment guidelines was expected to increase the cost of treatment in Zambia substantially. This talk will present results from the CGHD’s ongoing study of the costs and outcomes of ART in Zambia both before and after the switch to tenofovir; discuss the implications of the change for the overall cost and success of Zambia’s treatment program; and consider the tradeoff between quality and quantity in the response to HIV/AIDS.
Related Questions
- Im very interested in undergoing the Gerson Therapy, but I simply cant afford to go to a clinic. What other options do I have?
- Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?
- What is the first-line therapy for the metabolic syndrome?
